The study, published Aug. 9 in Cell, treated 15 patients with Pseudomonas aeruginosa infections using a virus called PASA16 and antibiotics. Patients received a once- to twice-daily regimen for a minimum of eight days.
Of patients, 13 had good clinical outcomes, suggesting the virus could help patients for whom traditional treatments have failed previously, the authors said. The treatment had few minor side effects.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
